# Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies

> **NCT01332461** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5677 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol xinafoate combination
- **DRUG:** Other maintenance Treatments (OMT)

## Key facts

- **NCT ID:** NCT01332461
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 5677 (ACTUAL)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332461, "Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01332461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*